---
title: "Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291579477.md"
description: "Maxim Group analyst Jason McCarthy reaffirmed a Buy rating on Gain Therapeutics with an unchanged $7 price target, citing clinical momentum for GT-02287 in Parkinson's disease and its differentiated GCase strategy. The FDA clearance of the IND for a phase 2 study and upcoming data support this view. Roth MKM also maintained a Buy rating with an $8 target. Despite recent analyst optimism, GANX stock has dropped 38.2% over six months."
datetime: "2026-07-02T18:45:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291579477.md)
  - [en](https://longbridge.com/en/news/291579477.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291579477.md)
generator: "portal-rs"
---

# Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Gain Therapeutics. The associated price target remains the same with $7.00.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Jason McCarthy has given his Buy rating due to a combination of factors, including clinical momentum and a favorable competitive landscape for GT-02287 in Parkinson’s disease. The recent FDA clearance of the IND for a phase 2 PD study, along with upcoming nine‑month phase 1b data, supports continued development and underpins his confidence in Gain Therapeutics’ lead program.

He also views the failure of Bial’s GCase activator in phase 2 as reinforcing the differentiated potential of Gain’s GCase‑targeting chaperone approach. Because GT-02287 may exert broader cellular effects through protein folding and trafficking, and compares favorably to other GCase modulators such as Vanqua Bio’s VQ-101, McCarthy sees enhanced partnering prospects and long‑term value creation, justifying his unchanged $7 price target and Buy rating.

In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $8.00 price target.

GANX’s price has also changed moderately for the past six months – from $3.220 to $1.990, which is a -38.20% drop .

### Related Stocks

- [GANX.US](https://longbridge.com/en/quote/GANX.US.md)

## Related News & Research

- [BTIG Keeps Their Buy Rating on Shift4 Payments (FOUR)](https://longbridge.com/en/news/297163377.md)
- [09:22 ETAfecta Pharmaceuticals Granted New US Patent for Neuro-Immuno Modulators](https://longbridge.com/en/news/296921568.md)
- [36,178,149 Shares in The Goodyear Tire & Rubber Company $GT Acquired by BlackRock Inc.](https://longbridge.com/en/news/297280913.md)
- [Number of shares and votes in BioArctic AB (publ) as of August 31, 2026](https://longbridge.com/en/news/297542152.md)
- [New Buy Rating for Block (XYZ), the Technology Giant](https://longbridge.com/en/news/297161740.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**